The withdrawal of torcetrapib from drug development: implications for the future of drugs that alter HDL metabolism

Author： Howes Laurence G   Kostner Karam  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.16, Iss.10, 2007-10, pp. : 1509-1516

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Drug Withdrawal and Hyperphagia: Lessons from Tobacco and Other Drugs

By  

Current Pharmaceutical Design, Vol. 17, Iss. 12, 2011-04 ,pp. : 1173-1179

Bentham Science Publishers

Access to resources Recommend Favorite

The Metabolism of Anticancer Drugs by the Liver: Current Approaches to the Drug Development Process

By  

Current Drug Metabolism, Vol. 16, Iss. 7, 2015-09 ,pp. : 506-521

Bentham Science Publishers

Access to resources Recommend Favorite

An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs

By Phan Viet Hong   Tan Cindy   Rittau Anneliese   Xu Hongmei   McLachlan Andrew J   Clarke Stephen J  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 11, 2011-11 ,pp. : 1395-1410

Informa Healthcare

Access to resources Recommend Favorite

Will pharmacogenomics alter the role of patents in drug development?

By Eisenberg Rebecca S  

Pharmacogenomics, Vol. 3, Iss. 5, 2002-09 ,pp. : 571-574

Future Medicine

Access to resources Recommend Favorite

Clinical Drugs Undergoing Polymorphic Metabolism by Human Cytochrome P450 2C9 and the Implication in Drug Development

By  

Current Medicinal Chemistry, Vol. 18, Iss. 5, 2011-02 ,pp. : 667-713

Bentham Science Publishers

Access to resources Recommend Favorite